Microphysiological Systems World Summit 2024

June 10 – 14, 2024

Seattle Convention Center
Seattle, WA, USA

Poster Summary:

The use of human-relevant three-dimensional in vitro cell models have gained popularity as they better recapitulated key aspects of human tissues and tumor microenvironments. Methods for generating organoids, spheroids, and tumoroids have progressed to where scientists have the ability to recapitulate most human organs and cancer types ex vivo. These models are being used in many aspects of drug discovery and development, but adoption has been limited due in part to challenges related to sample handling, assay development, and the need for optimized instrumentation. Here, we present a novel automated workflow for drug safety and efficacy studies using patient-derived 3D tumor models. We have combined the use of spheroONE for automated sorting, isolation and dispensing of spheroids and Pu·MA System EC with low attachment flowchips for incubation and automated viability assays and biomarker detection. We used this workflow to analyze viability of colorectal cancer (CRC) tumoroids treated with different oncology drugs and compared their response to immortalized cell line (HCT116 spheroids) based assays. This automated workflow using the spheroONE and Pu·MA System EC enabling tumoroid dispensing for accurate drug testing eliminates sample disturbance, manual handling errors and provides consistent reproducible high-quality data. This platform is a valuable tool in a wide range of research areas enabling multiplex disease modeling, drug discovery, and personalized medicine.